Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS
José Ignacio Fernández-Velasco(Hospital Universitario Ramón y Cajal), Luisa María Villar(Evidence (Italy)), Jaime Masjuán(Universidad de Alcalá), Yolanda Aladro(School of the Art Institute of Chicago), Inés González‐Suarez, Paulette Esperanza Walo-Delgado(Universidad de Alcalá), Francisco Gascón(Instituto Cajal), Jens Kühle(University of Basel), Enric Monreal(Hospital Universitario Ramón y Cajal), Noelia Villarrubia(Universidad de Alcalá), Virginia Meca‐Lallana(School of the Art Institute of Chicago), Albert Saiz(Neurology, Inc), Luís Brieva(Hebron University), Lucienne Costa‐Frossard(Universidad de Alcalá), Aleksandra Maleska Maceski(University of Basel), Yolanda Blanco(Fundació Clínic per a la Recerca Biomèdica), Pedro Sánchez(Instituto Cajal), Ernesto Roldán(Hospital Universitario Ramón y Cajal), José Meca-Lallana, Cristina Íñiguez(Instituto Cajal), Guillermo Izquierdo(Hospital Universitario Virgen Macarena), Luís Antônio(Instituto Cajal), Eulalia Rodríguez‐Martín(Instituto Ramón y Cajal de Investigación Sanitaria), Ester Carreón Guarnizo(Instituto Cajal)
Cited by 65
Related Papers
A clinical approach to diagnosis of autoimmune encephalitis
|The Lancet Neurology|2016|4.4k
Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study
|The Lancet Neurology|2013|3.1k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k